XTX Topco Ltd Sells 18,566 Shares of Incyte Co. (NASDAQ:INCY)

XTX Topco Ltd lessened its holdings in shares of Incyte Co. (NASDAQ:INCY - Free Report) by 84.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,491 shares of the biopharmaceutical company's stock after selling 18,566 shares during the period. XTX Topco Ltd's holdings in Incyte were worth $241,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Retirement Systems of Alabama raised its position in shares of Incyte by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 34,620 shares of the biopharmaceutical company's stock worth $2,391,000 after purchasing an additional 139 shares during the period. Trust Point Inc. lifted its stake in Incyte by 5.0% in the fourth quarter. Trust Point Inc. now owns 3,282 shares of the biopharmaceutical company's stock valued at $227,000 after buying an additional 156 shares in the last quarter. Bank of Nova Scotia boosted its holdings in shares of Incyte by 0.8% in the fourth quarter. Bank of Nova Scotia now owns 21,694 shares of the biopharmaceutical company's stock valued at $1,498,000 after buying an additional 171 shares during the period. Mather Group LLC. increased its position in shares of Incyte by 26.4% during the fourth quarter. Mather Group LLC. now owns 828 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 173 shares in the last quarter. Finally, 180 Wealth Advisors LLC raised its holdings in shares of Incyte by 3.9% during the fourth quarter. 180 Wealth Advisors LLC now owns 5,231 shares of the biopharmaceutical company's stock worth $361,000 after acquiring an additional 195 shares during the period. Institutional investors own 96.97% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on INCY shares. Royal Bank of Canada increased their target price on Incyte from $64.00 to $67.00 and gave the stock a "sector perform" rating in a report on Wednesday. Truist Financial dropped their target price on Incyte from $74.00 to $72.00 and set a "hold" rating on the stock in a research report on Tuesday, March 18th. Stifel Nicolaus upped their price target on Incyte from $75.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, February 10th. JPMorgan Chase & Co. lowered their price objective on shares of Incyte from $70.00 to $68.00 and set a "neutral" rating on the stock in a report on Monday, April 21st. Finally, William Blair cut shares of Incyte from an "outperform" rating to a "market perform" rating in a report on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $73.53.

Insider Transactions at Incyte

In other Incyte news, EVP Sheila A. Denton sold 14,069 shares of the business's stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total value of $1,042,090.83. Following the completion of the sale, the executive vice president now owns 25,848 shares of the company's stock, valued at $1,914,561.36. The trade was a 35.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $67.69, for a total transaction of $1,340,735.83. Following the transaction, the executive vice president now directly owns 33,567 shares in the company, valued at $2,272,150.23. This represents a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 34,475 shares of company stock worth $2,424,751. Company insiders own 17.60% of the company's stock.

Incyte Stock Performance

Shares of INCY stock traded down $0.19 on Friday, reaching $61.84. The stock had a trading volume of 362,491 shares, compared to its average volume of 2,350,850. Incyte Co. has a 12 month low of $52.28 and a 12 month high of $83.95. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $11.97 billion, a price-to-earnings ratio of 229.37, a P/E/G ratio of 0.41 and a beta of 0.89. The firm's 50-day moving average is $62.77 and its two-hundred day moving average is $68.88.

Incyte (NASDAQ:INCY - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $1.16 EPS for the quarter, topping analysts' consensus estimates of $1.01 by $0.15. The firm had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $996.17 million. Incyte had a net margin of 0.77% and a return on equity of 0.05%. The company's revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.64 earnings per share. On average, research analysts expect that Incyte Co. will post 4.86 EPS for the current fiscal year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.